bioMerieux (BMXMF) Stock Price, News & Analysis

Company Overview

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Key Stats

• Today's Range: $142.45 to $142.45
• 50-Day Range: $128.95 to $143.47
• 52-Week Range: $93.50 to $143.47
• Volume: N/A
• Average Volume: 3 shs
• Market Capitalization: $16.86 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

BMXMF Stock Analysis - Frequently Asked Questions

How have BMXMF shares performed this year?

bioMerieux's stock was trading at $106.19 on January 1st, 2025. Since then, BMXMF shares have increased by 34.1% and is now trading at $142.45.
View the best growth stocks for 2025 here.

How do I buy shares of bioMerieux?

Shares of BMXMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 6/29/2025
• Next Earnings (Estimated): 9/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BMXMF
• CIK: N/A
• Web: www.biomerieux.com
• Phone: 33-04-78-87-20-00
• Fax: 33-04-78-87-20-90
• Employees: 14,600
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.08
• Current Ratio: 2.20
• Quick Ratio: 1.29

Sales & Book Value

• Annual Sales: $4.31 billion
• Price / Sales: 3.91
• Cash Flow: $4.48 per share
• Price / Cash Flow: 31.79
• Book Value: $38.50 per share
• Price / Book: 3.70

Miscellaneous

• Outstanding Shares: 118,360,000
• Free Float: N/A
• Market Cap: $16.86 billion
• Optionable: Not Optionable
• Beta: 0.73